146 related articles for article (PubMed ID: 19953095)
21. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
22. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
23. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
[TBL] [Abstract][Full Text] [Related]
24. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
25. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
26. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
27. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
Zidan J; Keidar Z; Basher W; Israel O
Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
[TBL] [Abstract][Full Text] [Related]
28. A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density.
Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Mijares V; González-Macías J
Eur J Endocrinol; 2006 Jul; 155(1):53-9. PubMed ID: 16793950
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
30. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Mondockova V; Adamkovicova M; Lukacova M; Grosskopf B; Babosova R; Galbavy D; Martiniakova M; Omelka R
BMC Med Genet; 2018 Sep; 19(1):174. PubMed ID: 30241506
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women.
Koller DL; Zheng HF; Karasik D; Yerges-Armstrong L; Liu CT; McGuigan F; Kemp JP; Giroux S; Lai D; Edenberg HJ; Peacock M; Czerwinski SA; Choh AC; McMahon G; St Pourcain B; Timpson NJ; Lawlor DA; Evans DM; Towne B; Blangero J; Carless MA; Kammerer C; Goltzman D; Kovacs CS; Prior JC; Spector TD; Rousseau F; Tobias JH; Akesson K; Econs MJ; Mitchell BD; Richards JB; Kiel DP; Foroud T
J Bone Miner Res; 2013 Mar; 28(3):547-58. PubMed ID: 23074152
[TBL] [Abstract][Full Text] [Related]
32. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Eastell R; Adams JE; Coleman RE; Howell A; Hannon RA; Cuzick J; Mackey JR; Beckmann MW; Clack G
J Clin Oncol; 2008 Mar; 26(7):1051-7. PubMed ID: 18309940
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women.
Rivadeneira F; van Meurs JB; Kant J; Zillikens MC; Stolk L; Beck TJ; Arp P; Schuit SC; Hofman A; Houwing-Duistermaat JJ; van Duijn CM; van Leeuwen JP; Pols HA; Uitterlinden AG
J Bone Miner Res; 2006 Sep; 21(9):1443-56. PubMed ID: 16939403
[TBL] [Abstract][Full Text] [Related]
34. Association between dietary phytoestrogen intake and bone mineral density varied with estrogen receptor alpha gene polymorphisms in southern Chinese postmenopausal women.
Luo D; Liu Y; Zhou Y; Chen Z; Yang L; Liu Y; Xu Q; Xu H; Kuang H; Huang Q; He M; Peng W
Food Funct; 2015 Jun; 6(6):1977-83. PubMed ID: 26001094
[TBL] [Abstract][Full Text] [Related]
35. Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer.
Love RR; Young GS; Laudico AV; Van Dinh N; Uy GB; Quang le H; De La Peña AS; Dofitas RB; Bisquera OC; Siguan SS; Salvador JD; Mirasol-Lumague MR; Navarro NS; Linh ND; Jarjoura D
Cancer; 2013 Nov; 119(21):3746-52. PubMed ID: 23963821
[TBL] [Abstract][Full Text] [Related]
36. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
Ward RL; Morgan G; Dalley D; Kelly PJ
Bone Miner; 1993 Aug; 22(2):87-94. PubMed ID: 8251768
[TBL] [Abstract][Full Text] [Related]
38. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.
Chang J; Powles TJ; Ashley SE; Gregory RK; Tidy VA; Treleaven JG; Singh R
Ann Oncol; 1996 Sep; 7(7):671-5. PubMed ID: 8905024
[TBL] [Abstract][Full Text] [Related]
39. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer.
Marttunen MB; Hietanen P; Titinen A; Roth HJ; Viinikka L; Ylikorkala O
Calcif Tissue Int; 1999 Nov; 65(5):365-8. PubMed ID: 10541761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
